GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Interest Coverage

Better Therapeutics (Better Therapeutics) Interest Coverage : 0 (At Loss) (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Better Therapeutics's Operating Income for the three months ended in Sep. 2023 was $-5.34 Mil. Better Therapeutics's Interest Expense for the three months ended in Sep. 2023 was $-0.52 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Better Therapeutics's Interest Coverage or its related term are showing as below:


BTTX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 152.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Better Therapeutics Interest Coverage Historical Data

The historical data trend for Better Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Better Therapeutics Interest Coverage Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Interest Coverage
- - - -

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Better Therapeutics's Interest Coverage

For the Biotechnology subindustry, Better Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Better Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Interest Coverage falls into.



Better Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Better Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Better Therapeutics's Interest Expense was $-1.49 Mil. Its Operating Income was $-38.26 Mil. And its Long-Term Debt & Capital Lease Obligation was $10.35 Mil.

Better Therapeutics did not have earnings to cover the interest expense.

Better Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, Better Therapeutics's Interest Expense was $-0.52 Mil. Its Operating Income was $-5.34 Mil. And its Long-Term Debt & Capital Lease Obligation was $7.72 Mil.

Better Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Better Therapeutics  (OTCPK:BTTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Better Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Better Therapeutics (Better Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
Elder Granger director 5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman officer: Chief Medical Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe director, officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry director, 10 percent owner, officer: See Remarks 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino director C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust 10 percent owner C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen officer: See Remarks 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum director, 10 percent owner, officer: Chief Executive Officer 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu director 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski officer: Chief Commercial Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds officer: Chief Product Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona director 1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust 10 percent owner 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104